Ellen J. Kim - Faculty Biosketch

Ellen J. Kim, MD

Professor of Dermatology at the Hospital of the University of Pennsylvania

Department: Dermatology

Contact information

Department of Dermatology
Perelman School of Medicine at the University of Pennsylvania
Room 721, 7th Floor - South Tower
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard
Philadelphia, PA 19104

Office: 215-662-2737
Fax: 215-615-4966

Education:
A.B. (East Asian Studies)
Harvard University, 1991.
M.D.
University of Pennsylvania, 1996.

Links
Official Website of the Department of Dermatology, University of Pennsylvania

Post-Graduate Training
Intern in Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 1996-1997.
Resident in Dermatology, Boston University School of Medicine/Tufts University School of Medicine, Boston, MA, 1997-2000.
Research Fellow, Department of Dermatology, Boston University School of Medicine, Boston, MA, 2000-2002.

Certifications
American Board of Dermatology (recertified 2020), 2000.

Permanent link

> Perelman School of Medicine > Faculty > Details

Description of Research Expertise

Clinical trials for cutaneous T-cell lymphoma (CTCL)

Description of Clinical Expertise

Cutaneous Lymphomas (T-cell and B-cell) and lymphoproliferative disorders
Graft vs Host Disease
Extracorporeal Photopheresis

Selected Publications

Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 92(3): 634-636, Mar 2025.

Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol Nov 2024 Notes: doi: 10.1016/j.jaad.2024.10.095.

Villasenor-Park J, Chung J, Kim EJ: Cutaneous B-cell Lymphomas/Cutaneous Oncology. Hematology Oncology Clinics. Fisher D (eds.). Elsevier, 38(5): 1111, October 2024.

Silva GS, Kim EJ, Barta SK, Chung J: Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature. Expert Rev Anticancer Ther 24(9): 819-827, Sep 2024 Notes: doi: 10.1080/14737140.2024.2379914.

Asare C, Chen J, Ottevanger R, Scarisbrick J, Olsen EA, Tawa M, Thornton S, Kim E, Khan N, Larocca C, Shinohara MM. : Systematic literature review to identify patient-reported outcome measures for patients with cutaneous T-cell lymphoma. International Dermatology Outcomes Measures 11th Annual Meeting, Washington D.C. April 2024.

Rastogi S, Kim EJ, Gelfand JM, Loren AW, Baumrin E: Chronic graft-versus-host disease-associated muscle cramps: severity and response to immunomodulatory therapies Transplant Cell Ther 24, Jan 2024 Notes: doi: 10.1016/j.jtct.2023.12.674. Epub ahead of print.

Weiner DW, Rastogi S, Lewis DJ, Cohen L, Choi S, Vittorio CC, Haun PL, Samimi SS, Villasenor-Park J, Bhansali RS, Chong EA, Landsburg DJ, Nasta SD, Schuster, Svoboda J, Kim EJ, Rook AH, Barta SK.: Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma. Dermatologic Therapy Dec 2023 Notes: https://doi.org/10.1155/2023/7625926.

Bagot M, Kim YH, Geskin LJ, Ortiz-Romero P, Kim E, Mehta-Shah N, Dereure O, Oro S, Beylot-barry M, Dalle S, Jacobsen E, Lansigan F, Ram-Wolff C, Khodadoust MS, Battistella M, Gru A, Moins-Teisserenc H, Zinzani PL, Viott J, Paiva C, Muller M, Porcu P.: Lacutumab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial. American Society of Hematology Annual Meeting, San Diego, CA Dec 2023.

Polgione B, Alexander-Savino CV, Kim EJ, Mangold AR, Desimone J, Wong H, Rumage AT, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH.: HyBryte™ Use in Early-Stage Cutaneous T-cell Lymphoma Front Drug Discov 3, Nov 2023.

Gunter S and Kim EJ: Impact of Guidelines from the 2011 International Society for Cutaneous Lymphomas on Registered and Pivotal Clinical Trials in Cutaneous T-Cell Lymphoma: A Retrospective Cohort Study. J Invest Dermatol 23: 3038-5. Nov 2023 Notes: doi: 10.1016/j.jid.2023.10.011. Epub ahead of print.